News
The Latest in Seeking Comprehensive GVHD Care
Meet Our New Executive Director, Lamekia Davis
For Lamekia Davis, assuming the role of executive director of the Meredith A. Cowden Foundation is a natural evolution of her life-long passion to help others that took hold when she was just a child. “When I was 11 years old, my mom was diagnosed with stage IV breast...
Leadership Update
Since the Foundation’s inception in 2007, the Cowden family’s multi-faceted understanding and lived experience with GVHD—both from the patient and caregiver standpoint—has informed the direction of the Foundation both through our founders, Gerry & Marti Cowden,...
Gerald W. Cowden Founder and Chair Emeritus, Meredith A. Cowden Foundation
Gerald W. Cowden Founder and Chair Emeritus, Meredith A. Cowden Foundation Gerald "Gerry" W. Cowden is a retired Cleveland-based attorney whose four-decade legal career focused on entrepreneurs, growing businesses, and the investors who support them. He received his...
Be an Advocate, Raise Awareness for GVHD
If you were alive in the 1980’s, you may have heard G.I. Joe impart this important piece of wisdom at the end of an episode: “Now you know…and knowing is half the battle.” The other half of the battle—as anyone living with a chronic disease like graft vs. host disease...
PRESS RELEASE: FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric...
New Treatment Breakthrough for Chronic GVHD: Niktimvo™ Approved by FDA
In a significant development for patients battling chronic graft-versus-host disease (GVHD), the U.S. Food and Drug Administration (FDA) has granted approval to Niktimvo™ (axatilimab-csfr), a groundbreaking anti-CSF-1R antibody. This approval marks a pivotal moment in...
Incyte Announces US FDA Grants Priority Review For Axatilimab For Chronic GVHD Treatment
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 27, 2024-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment...
Season 12 of the Marrow Masters Podcast
Check out the latest season of the Marrow Masters podcast. This season, titled "I'm Home, Now What?" dives into a crucial phase of the journey – the period after returning home. It offers invaluable insights, guidance, and support for individuals who have completed...
Lunch & Learn with the LINK – Nutrition and the Holidays
Serving up Nutritional Know How and Resources as We Gear Up for the Holidays When: Wednesday, December 13, 2023 at Noon EST Note: start time will vary by time zone The nbmtLINK invites you to participate in this FREE session. Register Here Today! A Telephone Support...
Chronic GVHD Webinar Presented by nbmtLINK – Improving Life for Patients
Improving Life for Patients with cGVHD with a Focus on Lung Issues, Psychosocial Support, a Personal Perspective, and More When: Wednesday, December 6, 2023 at Noon EST to 1:30 pm EST (1.5 hours) Note: start time will vary by time zone • Closed Captioning Available...